Sanofi (SNYNF) — SEC Filings
Sanofi (SNYNF) — 50 SEC filings. Latest: 6-K (Dec 29, 2025). Includes 47 6-K, 3 13F-HR.
Overview
Sanofi (SNYNF) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 6-K filed on Dec 29, 2025: On December 24, 2025, Sanofi announced an update regarding its tolebrutinib regulatory submission for non-relapsing secondary progressive multiple sclerosis. The company is providing this information as part of its reporting requirements for the month of December 2025.
Sentiment Summary
Across 50 filings, the sentiment breakdown is: 22 bullish, 28 neutral. The dominant filing sentiment for Sanofi is neutral.
Filing Type Overview
Sanofi (SNYNF) has filed 47 6-K, 3 13F-HR with the SEC between Feb 2025 to Dec 2025.
Recent SEC Filings (50)
Risk Profile
Risk Assessment: Of SNYNF's 43 recent filings, 0 were flagged as high-risk, 3 as medium-risk, and 40 as low-risk. The overall risk profile suggests relatively low risk with generally favorable filings.
Top Tags
pharmaceuticals (20) · drug-development (10) · drug-approval (6) · regulatory-approval (4) · clinical-trial (4) · regulatory-filing (4) · acquisition (4) · regulatory-update (3) · press-release (3) · clinical-trial-results (3)
Key Numbers
| Metric | Value | Context |
|---|---|---|
| Bond Issuance | $3 billion | Capital raised by Sanofi through the bond offering. |
| Reporting Period End Date | June 30, 2025 | Date of the unaudited condensed half-year consolidated financial statements |
| Prior Audited Financial Statement Date | December 31, 2024 | Reference point for comparison with current unaudited statements |
| Q3 2025 Sales | €11.5 billion | Represents a 3.1% increase year-over-year. |
| Q3 2025 Sales Growth | 3.1% | Indicates positive revenue performance. |
| Acquisition Value | $1.4B | Sanofi's proposed purchase price for Vigil Neuroscience |
| Bond Issue | EUR 1.5 billion | Capital raised by Sanofi |
Related Companies
Frequently Asked Questions
What are the latest SEC filings for Sanofi (SNYNF)?
Sanofi has 50 recent SEC filings from Feb 2025 to Dec 2025, including 47 6-K, 3 13F-HR. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of SNYNF filings?
Across 50 filings, the sentiment breakdown is: 22 bullish, 28 neutral. The dominant sentiment is neutral.
Where can I find Sanofi SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Sanofi (SNYNF) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Sanofi?
Financial highlights for Sanofi are available when 10-K or 10-Q filings are enriched with AI analysis. Check back as new filings are processed.
What is the investment thesis for SNYNF?
Investment thesis data for SNYNF will be available once enriched filings are processed.
Who are the key executives at Sanofi?
Executive information for Sanofi is extracted from SEC filings as they are enriched with AI analysis.
What are the main risk factors for Sanofi stock?
Of SNYNF's 43 assessed filings, 0 were flagged high-risk, 3 medium-risk, and 40 low-risk.
What are recent predictions and forward guidance from Sanofi?
Forward guidance and predictions for Sanofi are extracted from SEC filings as they are enriched.